GlassScriptPhysician profile
Randall Faulk
NPI 1043214976
$1,065.65
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $425 · 2020: $202 · 2021: $203 · 2022: $236.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $220.30 | 2019-2022 | |
| Pfizer INC. | $154.67 | 2019-2020 | |
| Abbvie INC. | $120.73 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $101.44 | 2020-2021 | |
| Lilly USA, LLC | $99.44 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $74.17 | 2019-2020 | |
| Astellas Pharma US INC | $55.16 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $38.70 | 2019-2022 | |
| Novo Nordisk INC | $38.00 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $26.53 | 2022 | |
| Allergan, INC. | $24.02 | 2019 | |
| Corium, LLC | $16.05 | 2022 | |
| Tris Pharma INC | $15.92 | 2022 | |
| Amarin Pharma, INC. | $15.31 | 2019 | |
| Ironshore Pharmaceuticals INC. | $13.61 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $13.22 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $12.98 | 2021 | |
| Lundbeck LLC | $12.75 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.65 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Faulk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.